Could skipping chemo be safer for early rectal cancer?

NCT ID NCT07669298

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tests whether close follow-up (active surveillance) is as good as chemoradiotherapy for preventing cancer return after early-stage rectal cancer removal. About 480 adults with intermediate-risk T1 rectal cancer will be randomly assigned to either regular checkups and scans for 5 years or a 5-week course of radiation plus chemotherapy. The goal is to see if surveillance causes fewer serious side effects while keeping cancer outcomes similar.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Active surveillance (regular checkups and scans) vs chemoradiotherapy (radiation plus capecitabine or 5-FU chemotherapy)

What this could lead to

If active surveillance works as well as chemoradiotherapy, patients with early rectal cancer could avoid harsh treatments and their side effects, while still staying safe from cancer recurrence.

What could go wrong

This is a mid-stage trial with 480 participants, so results may not apply to everyone. Active surveillance might miss cancer regrowth, and chemoradiotherapy has known risks like bowel problems or severe side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rectal cancer rectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Institute of Oncology in Warsaw

    RECRUITING

    Warsaw, Poland

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

  • University Clinical Centre

    RECRUITING

    Gdansk, 80210, Poland

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

  • University Hospital, Limoges

    NOT_YET_RECRUITING

    Limoges, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact